The partnership's first clinical trial will determine if a new treatment can restore beneficial gut microbiome species and improve symptoms.
We are innovating to help humanity achieve some of its most inspiring medical advancements in the 21st century. Read about Microba’s progress, partnership news and latest discoveries.
Bringing Microba’s world-leading metagenomic sequencing and bioinformatics together with Holobiome’s promising microbiome therapeutic pipeline.
Microba have partnered with Europe’s largest pathology provider, SYNLAB, to deliver leading gut microbiome analysis into Europe.
Microba launched an IBD Research and Development (R&D) program in 2019 to tackle IBD by mining the gut microbiome for novel biotherapeutics.
Professor Phil Hugenholtz, has been announced as the next Vice President of the International Society for Microbial Ecology (ISME).
Research study at Curtin University examining possible links between infant gut microbiome composition and the development of allergies.
Microba have partnered with US company Psomagen to deliver gut microbiome analysis technology to the US market.
Machine learning technology will be used to identify significant associations between microorganisms and genes to predict different disease states.
Microba have partnered with the Microbiome Research Centre (MRC) to power new gut microbiome research.